Patients on Alzheimer’s drug Leqembi see benefits over three years, Eisai study says CNBCLilly and Eisai Diverge on Alzheimer’s Drugs Long-Term Usage BloombergEisai, Biogen make case for long-term use of Alzheimer’s drug Leqembi with new data STATExpanding the Knowledge Profile and Treatment Capabilities of Lecanemab: Lynn Kramer, MD, FAAN Neurology LiveJapan’s Eisai eyes blood test for Alzheimer’s drug eligibility Nikkei Asia